The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis

M. Ferro, F. Del Giudice, G. Carrieri, G.M. Busetto, L. Cormio, R. Hurle, R. Contieri, D. Arcaniolo, A. Sciarra, M. Maggi, F. Porpiglia, M. Manfredi, C. Fiori, A. Antonelli, A. Tafuri, P. Bove, C. Terrone, M. Borghesi, E. Costantini, E. IlianoE. Montanari, L. Boeri, G.I. Russo, M. Madonia, A. Tedde, A. Veccia, C. Simeone, G. Liguori, C. Trombetta, E. Brunocilla, R. Schiavina, F. Dal Moro, M. Racioppi, M.D. Vartolomei, N. Longo, L. Spirito, F. Crocetto, F. Cantiello, R. Damiano, S.M. Di Stasi, M. Marchioni, L. Schips, P. Parma, L. Carmignani, A. Conti, F. Soria, P. Gontero, B. Barone, F. Deho, E. Zaffuto, R. Papalia, R.M. Scarpa, V. Pagliarulo, G. Lucarelli, P. Ditonno, F.M.G. Botticelli, G. Musi, M. Catellani, O. de Cobelli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number5276
JournalCancers
Volume13
Issue number21
DOIs
Publication statusPublished - 2021

Keywords

  • Bladder cancer
  • Intravesical BCG
  • Re-TURBT
  • SARS-CoV-2
  • Trans-urethral resection of bladder tumor

Cite this